Silvia Boni
Overview
Explore the profile of Silvia Boni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baiardi G, Cameran Caviglia M, Boni S, Di Paolo A, Marini V, Cangemi G, et al.
Antibiotics (Basel)
. 2025 Feb;
14(2).
PMID: 40001433
Dalbavancin (DAL) is a long-acting lipoglycopeptide active against Gram-positive bacteria, including multidrug-resistant isolates. A growing body of evidence supports its efficacy in various difficult-to-treat infections. DAL shows time-dependent bactericidal activity...
2.
Monti G, Cabrini L, Kotani Y, Brusasco C, Kadralinova A, Giardina G, et al.
Br J Anaesth
. 2025 Jan;
134(2):382-391.
PMID: 39753402
Background: The impact of noninvasive ventilation (NIV) managed outside the intensive care unit in patients with early acute respiratory failure remains unclear. We aimed to determine whether adding early NIV...
3.
Porretto M, Parente F, Del Puente F, Parisini A, Tigano S, Nelli M, et al.
J Prev Med Hyg
. 2024 Oct;
65(2):E273-E277.
PMID: 39431001
Introduction: Surgical site infections (SSIs) are among the most frequently encountered complications in prosthetic surgery, and are associated with increased hospitalization, costs and in-hospital mortality. There is no national system...
4.
Marin G, Boni S, Garay V, Limeres M
Medicina (B Aires)
. 2024 Oct;
84(5):929-936.
PMID: 39399933
Introduction: Clinical trials that involve medicines are performed in order to determine their effectiveness and safety. In Argentina, these studies are presented either to National Administration of Drugs, Food and...
5.
Boccardi D, Marini V, Baiardi G, Cameran Caviglia M, Sacco F, Piras F, et al.
Clin Chim Acta
. 2024 Jun;
561:119806.
PMID: 38852792
Background And Aims: Ceftobiprole is a recent 5 generation parenteral cephalosporin with antibacterial activity against a large range Gram+ and Gram- bacteria. Therapeutic drug monitoring (TDM) is an essential tool...
6.
Mattioli P, Grisanti S, Massa F, Morbelli S, Boni S, Beronio A, et al.
Epileptic Disord
. 2024 Apr;
26(3):407-411.
PMID: 38619369
No abstract available.
7.
Boni S, Sartini M, Del Puente F, Adriano G, Blasi Vacca E, Bobbio N, et al.
J Clin Med
. 2024 Jan;
13(2).
PMID: 38256530
In several settings, the COVID-19 pandemic determined a negative impact on the occurrence of healthcare-associated infection, particularly for on central lines associated bloodstream infections (CLABSI). In our setting, we observed...
8.
Massa F, Vigo T, Bellucci M, Giunti D, Emanuela M, Visigalli D, et al.
Neurol Sci
. 2024 Jan;
45(3):849-859.
PMID: 38169013
Introduction: Guillain-Barré syndrome associated with Coronavirus-2-related severe acute respiratory syndrome (COV-GBS) occurs as para- or post-infectious forms, depending on the timing of disease onset. In these two forms, we aimed...
9.
Cristina M, Spagnolo A, Sartini M, Carbone A, Oliva M, Schinca E, et al.
J Fungi (Basel)
. 2023 Sep;
9(9).
PMID: 37755021
has become a major concern in critical care medicine due to the increasing number of immunocompromised patients and candidiasis is the most frequent cause of fungal infections. and other fungal...
10.
Parisini A, Boni S, Blasi Vacca E, Bobbio N, Del Puente F, Feasi M, et al.
Antibiotics (Basel)
. 2023 Aug;
12(8).
PMID: 37627698
The SARS-CoV-2 pandemic caused an increase in intensive care unit (ICU) hospitalizations with a rise in morbidity and mortality; nevertheless, there is still little evidence on the impact of the...